Project neuroARTEMIS

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-59
SponsorWake Forest University Health Sciences

About this trial

The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.

Eligibility criteria

Qualifiers

18-59 years old

Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

Confirmed HIV diagnosis

Current receipt of daily oral antiretroviral therapy (ART) medication

Disqualifiers

Acute brain infection (e.g., neurosyphilis, toxoplasmosis)

Acutely symptomatic bipolar I or psychotic disorder

Prescription for immunomodulatory medications or other immunotherapy

Any MRI contraindications

Trial design

Treatments tested in this trial

  • ARTEMIS
  • Contingency management for Antiretroviral (ARV) adherence

Treatment groups

189 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Wake Forest University Health Sciences

Lead sponsor

Florida International University

Collaborator

National Institutes of Health (NIH)

Collaborator

National Institute on Drug Abuse (NIDA)

Collaborator